echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Osaikon's subsidiary zoledronic acid concentrated solution for injection obtained the notification of acceptance of the listing application

    Osaikon's subsidiary zoledronic acid concentrated solution for injection obtained the notification of acceptance of the listing application

    • Last Update: 2021-11-04
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On October 21, Osaikang issued an announcement stating that its wholly-owned subsidiary, Jiangsu Osaikang, had recently received the "Notice of Acceptance" for the marketing application for concentrated zoledronic acid solution for injection issued by the National Medical Products Administration


    The concentrated solution of zoledronic acid for injection has been approved for marketing in the United States, Europe, Japan and Canada


    Zoledronic acid is a potent inhibitor of osteoclast activity.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.